BioSpace News Archive

Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell 3000 Ò Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective Monday, June 29 th 2020 after the U.S. market opening. Annual Russell indexes reconstitution captures t

SubioMed, Inc. (“SubioMed™” or the “Company”), a pioneer in the invention and development of disruptive Suspension Biomechanics™ technology addressing critical elements of gait and balance, today announced that it has successfully completed its initial equity financing round of $1.5M. The common stock offering saw insider participation, in addition to investments from individual angel investors. Patrick Kullmann, Chairman and Chief Executi

Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumab’s use with viral infections, including COVID-19. Dr. Singh stated, “With the present pandemic, the need for further research is essential to both understand and inhibit COVID-19’s continual spread. This opportunity with Nascent Biotech allows me to continue my medical work in viral infectio

Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, today announced that it has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OH

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the Gritstone management team will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET to present data from the ongoing Phase 1 studies of its immunotherapy product candidates GRANITE and SLATE. Phase 2 study plans will also be dis

Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Leila Alland and Ms. Jane Wasman to its Board of Directors, effective immediately. Dr. Leila Alland brings extensive experience in oncology drug development to her role at Cytovia Therapeutics. Dr. Alland is currently Chief Medical Officer at PMV Pharma, a leader in the discov

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has again affirmed its strategic commitment to leadership in cybersecurity risk management and cybersecurity protection by partnering with Clearwater, the leading provider of enterprise cyber risk management solutions for the healthcare industry.

Fewer Than One Percent of All Rated Organizations Have Received the Distinction With This Consistency

Docbot, Inc., a privately-held company developing leading artificial intelligence (AI)-driven healthcare applications, today announced the first subjects enrolled at Gastro Health in a pivotal trial to validate Ultivision™ AI imaging platform for adenoma detection during colonoscopy screenings.

Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that Ciara Kennedy , Ph.D., president and CEO, plans to present an overview of the company and update on their clinical development